Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 666 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma August 30, 2021 Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... November 12, 2021 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 Load more HOT NEWS Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... The Unique Challenges Teenagers and Young Adults With Cancer Face: An...
